Company intelligence / Profile preview

coding.bio

Oxford, England, United Kingdomcoding.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Coding Bio is developing a high-throughput, ML-driven platform to rapidly screen and engineer modular cell-based immunotherapies such as CARs and BiTEs. The company focuses on optimizing immune activation rather than just protein binding, aiming to accelerate the development of best-in-class cancer therapies. No clinical results have been published yet.

Therapeutic areas: Oncology
Modalities: Cell therapies (including CARs and BiTEs)Modular immunotherapies
Industry: Biotech

Drug pipeline

1 asset

BCMA/FcRL5 TriTE

Preclinical

Beyond the preview

Go deeper on coding.bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coding.bio.

Explore the full profile